

RESPIRI APPOINTS FORMER SENIOR GLOBAL PFIZER EXECUTIVE MARIO GATTINO AS CHIEF EXECUTIVE OFFICER

Respiri Limited (ASX: RSH) is pleased to announce the appointment of Mario Gattino as its Chief Executive Officer. Mario has over 25 years' experience in senior leadership positions within the medical industry. His track record in commercialising and managing sales of drug and medical device products in multiple countries will be invaluable in helping Respiri achieve its commercial milestones.

The appointment comes as the Company approaches a key inflection point with the 2018 global launch of its over-the-counter asthma monitoring device, AirSonea.

HIGHLIGHTS:

- Mr Gattino has held senior leadership positions at Pfizer, one of the world's largest pharmaceutical companies, in the USA and Europe
- He has a long successful track record in commercialising drug and device products globally and growing sales in multiple markets including the USA, Europe and Asia
- He is an expert in sophisticated stakeholder management, portfolio and business development via M&A and licensing, brand commercialisation, business innovation and profit generation
- His experience in launching and managing products in several countries, formulating and executing commercialisation plans, and dealing with local regulators will be invaluable to Respiri at this important juncture

Mario spent 20 years working with Pfizer including serving as the Chief Operating Officer & Regional Business Director responsible for operational issues in ten Northern European countries. He also held the position of Country Chief Executive Officer in Budapest including responsibility for logistics and distribution in central and Eastern Europe. Mr Gattino's latest role was Vice President and General Manager (ANZ) for Ikaria Inc., a drug-medical device company, where he turned around its Australia and New Zealand business and was responsible for spearheading an expansion into APAC.

Other key roles he has held include Managing Director for Perrigo ANZ, a company that makes a wide range of consumer healthcare products, and was the key advisor to an in-vitro diagnostic start-up where he developed its global commercialisation strategy and successfully raised capital.

Mario holds an MBA from the University of NSW (AGSM) and a Bachelor of Applied Science (Medical Administration) from La Trobe University.

Leon L'Huillier, Respiri's Chairman, said "Respiri is very fortunate to attract someone of Mario's standing. He is ideally suited to lead the company into its commercialisation phase as we look to launch AirSonea in a number of key markets next year. We welcome him to our team."

APPOINTMENT OF MR MARIO GATTINO AS AN EXECUTIVE DIRECTOR

Mr Gattino will be appointed as a Director of Respiri Limited after the Annual General Meeting in 2017. The composition of the Board is regularly reviewed to ensure that its size, mix of skills and experience is appropriate for the stage of the company development. Dr Tim Oldham will retire from the Board at the conclusion of the 2017 Annual General Meeting. Future partnerships or alliances may involve further Board appointments.

SUMMARY OF MR GATTINO'S KEY CONTRACTUAL TERMS

Item	Details
Role	Chief Executive Officer
Term	No fixed term, commencing 1 December 2017
Fixed Remuneration	<ul style="list-style-type: none"> • \$300,000 per annum, subject to annual review by the Board • Plus associated benefits customary to a role of this nature
Variable (at risk) Remuneration	<ul style="list-style-type: none"> • A short term incentive of up to 50% of total fixed remuneration subject to individual and company performance outcomes and provided in cash. Performance targets will include but not limited to the delivery of functional product prototypes, regulatory approvals, contract manufacturing and significant partner outcomes. • A long term incentive structure over 2, 3 & 4 years to reflect growth in shareholder value that will be largely driven by the delivery of key strategic objectives. Respiri operates in the global health technology business that has multiple commercial opportunities and due to commercial sensitivities targets will be published after the performance period. <ul style="list-style-type: none"> – The options will be issued to Mr Gattino and/or his nominee and issued no later than one month after the date of the Annual General Meeting. – 10,000,000 unlisted options exercisable on or before 31 December 2019. The exercise price of each option will be set at \$0.10 per option. – 10,000,000 unlisted options exercisable on or before 31 December 2020. The exercise price of each option will be set at \$0.15 per option. – 5,000,000 unlisted options exercisable on or before 31 December 2021. The exercise price of each option will be set at \$0.20 per option. • The issue of unlisted options is consistent with the Company's historical practice.
Notice, termination and termination payments	<ul style="list-style-type: none"> • The Company may terminate employment at any time on six months' notice or at the discretion of the Board, payment in lieu of notice • The CEO may terminate employment with the Company at any time on three months' notice or, at the Company's election, payment in lieu of notice

Leon L'Huillier
Executive Chairman

Ph: 1800 476 632

For personal use only

ABOUT RESPIRI LIMITED

Respiri Limited (ASX:RSH) is a medical technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

For personal use only